[theold]

Pfizer has signed an equity subscription agreement to invest $95m (€90.5m) to acquire 8.1% of French firm Valneva’s share capital for €9.49 per share.

The equity investment by Pfizer via a reserved capital increase will further support the Lyme partnership between the two firms.


The companies also modified the terms of their partnership and licence agreement for investigational multivalent protein subunit vaccine candidate for Lyme disease, VLA15.

https://www.pharmaceutical-technology.co...e-valneva/